{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014403","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.208000+00:00","generated_at":"2026-06-11T18:38:05.913304+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023","bullets":["Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.","Cash and equivalents $27.7M; management expects runway into Q4 2024.","R&D expenses down to $2.2M from $6.8M; G&A down to $1.7M from $15.6M YoY.","ATRN-119 Phase 1/2a enrollment ongoing; initial safety and PK data expected Q4 2023.","Gabriela Gruia, M.D., appointed to Board of Directors; over 25 years clinical and regulatory experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014403","json":"https://secwatch.observer/filing/0001558370-23-014403.json","markdown":"https://secwatch.observer/filing/0001558370-23-014403.md","text":"https://secwatch.observer/filing/0001558370-23-014403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/0001558370-23-014403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/apre-20230810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:38:05.913304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0977c13820010a1b0994cf619b11782e81f5f060","claim":"Aprea Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $3.3 million, EPS $0.87 per basic share.","evidence_excerpt":"The Company reported a net loss of $3.3 million ($0.87 per basic share) on approximately 3.7 million weighted-average common shares outstanding for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/0001558370-23-014403-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"$0.87 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}